Expansion of SVN-015 into Depression Following Positive Preclinical Data
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (‘CNS’) disorders, announces the expansion















